Arcutis Technologies Q2 product revenue surges

Arcutis Biotherapeutics

06/08/2025 21:10

Overview

Arcutis Q2 2025 net product revenue rises 164% yr/yr to $81.5 mln

Company reports net loss of $15.9 mln, an improvement from prior year

FDA approves ZORYVE foam for scalp and body psoriasis, boosting sales

Outlook

Company anticipates Q4 approval for ZORYVE cream 0.05% in children

Company focused on expanding ZORYVE's approved uses

Arcutis advancing pipeline with ARQ-234 for atopic dermatitis

Result Drivers

STRONG DEMAND - Revenue growth driven by increased demand for ZORYVE foam and cream, particularly following FDA approval for new indications

PRESCRIPTION GROWTH - Over 439,000 prescriptions filled for ZORYVE cream 0.3% and 405,000 for ZORYVE foam since launch, reflecting high patient and physician satisfaction

PIPELINE ADVANCEMENT - Continued advancement of ZORYVE and ARQ-234 pipeline, with new studies and regulatory submissions underway

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$81.50 mln
Q2 Net Income
-$15.89 mln
Q2 Basic EPS
-$0.13
Q2 Operating Expenses
$96.12 mln
Q2 Operating Income
-$14.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $20.00, about 23.4% above its August 5 closing price of $15.33

Press Release: ID:nGNX91BvHc

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)